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Abstract
Background: This study aims to rank policy concerns and policy-related research issues in order to identify policy
and research gaps on access to medicines (ATM) in low- and middle-income countries in Latin America and the
Caribbean (LAC), as perceived by policy makers, researchers, NGO and international organization representatives,
as part of a global prioritization exercise.
Methods: Data collection, conducted between January and May 2011, involved face-to-face interviews in El
Salvador, Colombia, Dominican Republic, and Suriname, and an e-mail survey with key-stakeholders. Respondents
were asked to choose the five most relevant criteria for research prioritization and to score policy/research items
according to the degree to which they represented current policies, desired policies, current research topics, and/or
desired research topics. Mean scores and summary rankings were obtained. Linear regressions were performed
to contrast rankings concerning current and desired policies (policy gaps), and current and desired research
(research gaps).
Results: Relevance, feasibility, and research utilization were the top ranked criteria for prioritizing research. Technical
capacity, research and development for new drugs, and responsiveness, were the main policy gaps. Quality
assurance, staff technical capacity, price regulation, out-of-pocket payments, and cost containment policies, were
the main research gaps. There was high level of coherence between current and desired policies: coefficients of
determination (R
2) varied from 0.46 (Health system structure; r = 0.68, P <0.01) to 0.86 (Sustainable financing; r = 0.93,
P <0.01). There was also high coherence between current and desired research on Rational selection and use of
medicines (r = 0.71, P <0.05, R
2 = 0.51), Pricing/affordability (r = 0.82, P <0.01, R
2 = 0.67), and Sustainable financing
(r = 0.76, P <0.01, R
2 = 0.58). Coherence was less for Health system structure (r = 0.61, P <0.01, R
2 = 0.38).
Conclusions: This study combines metrics approaches, contributing to priority setting methodology development,
with country and regional level stakeholder participation. Stakeholders received feedback with the results, and we
hope to have contributed to the discussion and implementation of ATM research and policy priorities in LAC.
Keywords: Access to medicines, Health systems, Health systems research, Interviews, Latin America and the
Caribbean, Priority setting, Web survey
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The achievement of the health-related Millennium De-
velopment Goals [1] strongly depends on health system
capacity. Research for health has been recognized as
crucial to generate innovations driven by health prob-
lems and diseases that disproportionally affect low-
and middle-income countries (LMICs), as well as to
provide the scientific and technical evidence needed
to promote decision-making effectiveness regarding re-
source allocation, policies, and health system strengthe-
ning interventions [2-6].
Since 1990, the Commission on Health Research for De-
velopment identified a huge inequity in health research fi-
nancing, with only 4.4% of global resources directed to
health problems of developing countries. By 2000, this per-
sistent imbalance between spending and disease burden
was characterized as the ‘10/90 gap’ [7,8]. International
political declarations call for increased and more equitable
funding for research, and to make it more responsive to
health systems needs in LMICs [3,4,7,9]. In this sense, set-
ting research priorities at national, regional, and global
levels is a core strategy aimed at closing the gap [5,7,10].
The delivery of medicines to people in need is an essen-
tial component to strengthen health systems effectiveness.
Ensuring access to medicines (ATM) depends on efforts re-
lated to different domains such as sustainable financing,
the existence of a network of reliable health services, and
an efficient supply chain management [11,12]. Therefore, it
is crucial to generate reliable and accurate information on
different ATM domains that could be used for strengthen-
ing health systems. Yet, in order to make research respon-
sive to health systems needs in LMICs, priority-setting
processes can be useful for targeting research that presents
the greatest potential public health benefit [10].
As part of a global exercise on priority setting for
health policy and research on ATM in LMICs, coor-
dinated by the Alliance for Health Policy and Systems
Research (AHPSR) [13], two studies involving Latin
American and the Caribbean (LAC) LMICs were carried
out by researchers from the Sergio Arouca National
School of Public Health, Brazil. One of them, published
in 2013 [14], consisted of a scoping study that identified
ATM research issues and gaps through the analysis of
the scientific publication trends in LAC. It showed that,
even though a lot of effort has been made and achieve-
ments have been reached in some countries, research on
ATM still remains a challenge for countries in Latin
America and the Caribbean. The second study, presen-
ted in this paper, aimed at ranking policy/research items,
in order to identify policy and research gaps on ATM in
LMICs of LAC, as perceived by policy makers, resear-
chers, and non-governmental organization (NGO) and
international organization representatives; the results of
both were used in the global exercise [13].
The main objectives of the AHPSR global study were
to identify priority policy issues in ATM relevant for
LMICs, to identify research questions that would help
address these policy issues, and to prioritize these re-
search questions in a health policy and systems research
(HPSR) agenda [13]. Different researchers have studied
LMICs from other geographic regions.
Methods
The data collection strategy conducted from January to
May 2011 involved two approaches: face-to-face inter-
views with key-stakeholders from selected countries and
an e-mail survey. Both approaches used the same ques-
tionnaire, in which a single list of items was ranked. Re-
spondents were asked to score each policy/research item
according to the degree to which it represented a cur-
rent policy, a desired policy, a current research topic,
and/or a desired research topic.
The methodology adopted in this study was adapted
from Urcullo et al. [15], whose method was applied in a
similar study on priority setting for HPSR, on health fi-
nancing and human resources for health.
Research settings and participants selection
Face-to-face interviews were carried out in four countries:
El Salvador; Colombia, Dominican Republic, and Suriname.
Country selection criteria covered the inclusion of both
lower- (El Salvador) and upper-middle income countries
(Colombia, Dominican Republic, and Suriname) from all
Pan American Health Organization (PAHO) sub-regions
(Central America, South America, and the Caribbean);
existence of local researchers working on ATM and related
issues; and agreement from country representatives to par-
ticipate in the study. As medicines were seen as a sensitive
political subject, PAHO officers mediated the identification
of countries and the invitation to join the study.
In each country, interviews with 12 stakeholders were
planned: five government decision makers (two high
level decision makers at the Ministry of Health (MoH);
one person in charge of pharmaceuticals at the MoH;
one member of the national congress health commis-
sion; one person from the drug regulatory authority);
one member of medical and one member of pharmaceu-
tical professional associations; one representative of in-
ternational organizations (World Health Organization/
PAHO; USAID; Inter-American Development Bank; World
Bank); two researchers working on ATM; and two NGO
representatives. Local partners from PAHO offices sup-
ported the identification of interviewers.
The e-mail survey was carried out to expand the cover-
age of countries and key stakeholders. It was planned to
include one person in charge of pharmaceuticals in the
MoH and two activists from NGOs with relevant actions
on ATM from each LMIC in the region (excluding the
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ATM in LAC in the previous 10 years; 23 international
agency representatives (PAHO focal points on medicines);
and persons from the pharmaceutical industry with ATM
projects in the region. We were able to identify 112 poten-
tial respondents. After sending the first invitation, two
follow-up contacts were made requesting a reply.
Questionnaire structure
The first step in the development of the questionnaire
was the selection of a list of items that would be sub-
jected to ranking. Items were generated as exhaustively
as possible and were phrased as to reflect both policy is-
sues and research topics, pertinent to the discussion of
ATM. Those policy/research items were developed in an
AHPSR expert meeting, held in Cambodia in 2010 – a
preparatory meeting for regional prioritization exercises,
which were intended to subsidize a global prioritization
effort on ATM research [13]. Regional team leaders ag-
reed upon an analytical framework based on the WHO
four ATM dimensions (rational selection and use, af-
fordable prices, sustainable financing, and reliable health
and supply systems) and determinants rooted in local,
national, and international contexts [12]. For this regio-
nal exercise, items generated were organized in a matrix
reflecting the analytical framework (Table 1).
The questionnaire was composed of five parts: I) inter-
viewee profile (background, educational level and affili-
ation); II) an open-ended question regarding access to
medicines; III) ranking of research prioritization criteria;
IV) policy priority rankings; and, V) research priority
rankings. This paper discusses parts III, IV and V.
In part III, interviewees and respondents were pro-
vided with a list of prioritization criteria for research and
asked to rank them, in an attempt to identify what
should drive research priority definitions on ATM. It
also elucidates which criteria were more likely to guide
respondents’ rankings of the research alternatives.
In part IV, interviewees and respondents were pro-
vided with a list of items (Table 1) and asked to rank
them, as they would represent policy priorities regarding
the following aspects:
 Policies being carried out by the government
(current policies);
 Policies that the government should be carrying out
(desired policies).
In part V, interviewees and respondents were asked to
rank the same list of items, but in this case, as they would
reflect research priorities on ATM:
 Topics being investigated at national research
centers (current research);
 Research topics required for public health policies
(desired research).
In all ranking parts of the questionnaire, items could
be added (by means of an “other” option) if participants
felt that the provided list was incomplete.
All research materials were produced in Portuguese
and translated into English and Spanish. For face-to-face
interviews, a printed list of items was given to the inter-
viewees in order to help them think about each item.
Trained members of the research team, who performed
pre-tests and meetings to standardize questionnaire appli-
cation, conducted the interviews. The e-mail survey ver-
sion contained explanations and instructions to assure a
common comprehension and filling of the questionnaire.
Ranking and scoring procedures
Interviewees and e-mail survey respondents were asked
to choose the five most relevant criteria for research prio-
ritization (part III) and policy/research items (parts IV
and V), and sort them from 1 (top priority) to 5 (5
th prio-
rity). Selected criteria and policy/research items (Table 1)
received a score for each interviewee/respondent (from 5
to 1, with higher scores for the most important and lower
scores for the least important within the chosen list). Cri-
teria and policy/research items that were not among the
five most relevant received a score of 0.
We calculated average scores for each country visited
as well as for the e-mail survey responses. Total scores
for each criterion and summary rankings for each as-
sessed aspect (current and desired policies; current and
desired research) were obtained by summing those ave-
rage scores.
Coherence analysis
A coherence analysis was performed in order to answer
the following questions:
1. How well does the government respond to the needs
of the population? – By comparing answers about
policies being carried out by the government
(current policies) vs. policies that the government
should be carrying out (desired policies).
2. Is scientific evidence being generated to support
policies that respond to the needs of the population? –
By comparing answers about policies that the
government should be carrying out (desired policies)
vs. topics being investigated at national research
centers (current research).
3. Is research moving in the right direction? – By
comparing answers about topics being investigated
at national research centers (current research) vs.
research topics required for public health policies
(desired research).
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* generated by the regional meeting in Cambodia according to the World Health Organization framework for access to medicines
and Health System Level
**
WHO Framework for ATM
1. Rational selection and use of medicines 2. Pricing/affordability 3. Reliable health system/health
system structure
4. Sustainable financing
I. Individual, household,
and community level
1a) Information asymmetry (user knowledge level;
communication and language barriers – as for
ethnic minorities)
2a) High out-of-pocket payment 3a) Geographical accessibility: physical
barriers; distance to facilities;
remoteness (combination of
physical barriers and infrastructure
weakness)
4a) Community financing
arrangements
2c) Community participation in medicine
delivery arrangements 4b) Role of government
subsidies at community
level
1b) Health seeking behavior, preference for
private care, preference for secondary level of
care (bypass primary health care), self-
medication 4c) Focal models of subside 3e) Traditional medicine (e.g., unclear
distinction between allopathy and
non-allopathy) 1c) Beliefs about illness and treatment (traditional
practices; demand for injections and branded
medicines; prescribers and dispensers
perception of quality of drugs)
II. Public and private
health service delivery
channels
1d) Impact of advertisements on medicines;
incentives (or lack of, leading to private or
dual practice); medicines becoming a source
in financing for health services
2d) Medicine price variation according to
geographical location (e.g., urban/rural
differences, higher prices in remote
areas); price differential between public
and private
3b) Distribution systems and supply
chains
4d) Health provider payment
methods
4e) Health insurance coverage
and models
3c) Pharmaceutical services at local
level
1e) Staff capacity for rational prescription and use
of medicines; training curriculum
3d) Informal markets – substandard
quality and counterfeit medicines
3f) Staff and technical capacity: for
supply management; with
managerial, interpersonal, and
information technology (IT) skills;
with local language skills
1f) Clinical treatment guidelines, and essential
medicines list: development; incentives for
implementation; operational mechanisms;
standardization (including between private
and public sectors)
3g) Responsiveness to patient needs;
differential responsiveness
between public and private
1g) Incentives for rational use of medicines and
for implementation of generic policy
3j) Availability of medicines (especially
in public sector)
III. Health sector 1h) Staff deployment 2b) Opportunity costs 3h) Public-private mix: reliance on pri-
vate sector delivery; public-private
partnerships and their role in ac-
cess to medicines
4f) Government budgets for
medicines
2e) Medicine price information system 4g) Reimbursement policies
1i) Pharmacovigilance, information on adverse
drug reaction, and other problems related to
medicines
2f) Impact of prices on access 4h) Cost containment policies 3i) Central procurement policies vs.
decentralization 2g) Policy and regulation for medicines
price 3k) Quality assurance
2h) Incentives for implementation of
generic policy
3l) Coordination between health
policies and medicines policies;
referral policy/referral system
1j) Medicine information system (not only price
information)/competing with medicines
advertisement
3m) Monitoring and evaluation
systems; funding for monitoring
and evaluation
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1Table 1 Policy/research items
* generated by the regional meeting in Cambodia according to the World Health Organization framework for access to medicines
and Health System Level
** (Continued)
IV. Beyond the health
sector
1k) Intersectoral initiatives (e.g., rational use of
medicines in schools – role of Ministry of
Education)
2i) Patents and intellectual property issues 3n) Governance and governing: law
and regulation enforcement;
transparency and accountability
4i) Donor funding;
harmonization and
alignment; verticalized
donor support
2j) Finance policies: taxes, autonomy,
privatization; exemption systems
4j) Patents and intellectual
property issues
3o) Regional integration and economic
cooperation (example: UNASUL,
MERCOSUL)
4k) Finance policies: taxes,
autonomy, privatization
2k) Trade and economic goals (impact of
health sector policies outside the health
sector)
4l) Trade and economic goals
(impact of health sector
policies outside the health
sector)
3p) Promotion of research and
development – new drugs/
neglected diseases.
2l) Budget allocation to health 4m) Budget allocation to
health
2m) Medicine production 3q) Medicine production
*Item codes reflect the order in which they appeared in the questionnaire. Here they are presented according to Health System Level.
**Health System Levels according to Bigdeli et al. [12]: I. Individual, household and community; II. Health service delivery; III. Health Sector; IV. Beyond the health sector (Public policies cutting across sectors; and,
International and regional level).
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1Linear regressions depicted on scatter plots were per-
formed to test these relationships. Strength and direction
of association were estimated by calculating the cor-
relation coefficient (Pearson’s r) and its statistical sig-
nificance (P value). Data linearity fit was expressed by
coefficients of determination (R
2), used as coherence
indicators.
We assumed that interviewees and respondents are le-
gitimate spokespersons to indicate priorities on behalf of
the population, and are informed enough to point out
policies governments are currently carrying out and
topics currently being investigated at national research
centers.
The National School of Public Health Ethics Research
Committee approved the project. All interviews were
conducted after the signing of a written informed con-
sent. In the case of the e-mail survey, the informed con-
sent was presented to participants as the first page of
the form and they were asked to fill it in if they agreed
to participate.
Results
Forty-nine interviews were completed in country visits
(Table 2). Two of the selected stakeholders were unavail-
able in Suriname and El Salvador. In Colombia, a higher
number of stakeholders were included, due to an in-
creased interest and participation of NGO representa-
tives during data collection.
From the target of 112 stakeholders, 98 e-mails were
successfully sent (14 emails bounced), and a final re-
sponse rate of approximately 35.7% was reached after at
least two attempts. The final sample of respondents in
the e-mail survey was mainly composed of researchers
(48.6%) and NGO representatives (22.9%) – which ex-
panded the representativeness of those types of stake-
holders in the study, followed by international agency
representatives (mainly PAHO officers; 14.3%), and MoH
representatives (11.4%). There was a low representative-
ness of pharmaceutical industry respondents, with only
one response.
Research prioritization criteria
The highest ranked criterion that should be applied
in the definition of research priorities on ATM was
Relevance, which was also the most cited in
Colombia, Dominican Republic, and in the e-mail sur-
v e y( T a b l e3 ) .T h es e c o n dc r i t e r i o nw a sFeasibility,
and the third Research utilization.T h el a t t e r ,w a sa l s o
one of the top three ranked criteria in Colombia,
Suriname, and in the e-mail survey. Whereas the first
item implies a relationship between the measurement
or magnitude of a problem and its degree of priority,
the others refer to more operational or pragmatic as-
pects of research – denoting expectations towards the
usefulness of policy research as an input to public
management and decision-making.
In El Salvador, political and rights-based criteria were
considered more important than managerial ones. These
criteria were also high ranked in the Dominican Repub-
lic and in Suriname. Responsiveness to the National
Health Policy was considered important in the e-mail
survey (Table 3).
It is important to notice that criteria were identified
and ranked for scoring policy relevance of research
items were used implicitly by participants, and were
scored separately (i.e., participants gave one overall
score to each item according to the degree to which
it was desired research, and not according to each
criterion).
Policy and research rankings
Table 4 shows the three top ranked policy/research
items in each assessed aspect, as well as their summary
rankings.
One single item from the domain of Rational Selection
and Use of Medicines scored the highest on almost all
categories (current and desired policies, and current and
desired research): (1f) Clinical treatment guidelines, and
Essential Medicines List.
On the other domains, the highest ranked items re-
garding current policies were also the highest ranked for
desired policies: (2g) Policy and regulation for medicines
Table 2 Number of respondents by country
Information source Number of respondents
Country visits 49
Colombia 15
Dominican Republic 12
El Salvador 11
Suriname 11
E-mail survey 35
Argentina 3
Bolivia 1
Brazil 13
Colombia 3
Costa Rica 1
Ecuador 6
USA 4
Guatemala 1
Mexico 1
Peru 2
Total 84
Source: Authors.
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bility – Reliable Health System/Health System Structure;
and (4f) Government budgets for medicines – Sustain-
able Financing.
With respect to current research, the main items were
(1f) clinical treatment guidelines and essential medi-
cines list; (2f) impact of prices on access; (3j) availability
of medicines; and (4e) health insurance coverage and
models.
In the domain of Rational Selection and Use of Medi-
cines, the main desired research items were (1f) clinical
treatment guidelines and essential medicines list, (1e)
staff capacity and training, and (1i) pharmacovigilance,
demonstrating an overall demand for investigations that
focus on health service delivery and health sector levels.
Regarding Pricing/Affordability, (2f) impact of prices on
access, (2g) policy and regulation for medicines price,
and (2a) high out-of-pocket payment received the high-
est summary rankings. In the domain of Reliable Health
System/Health System Structure, the main topics re-
quired for the design of public health policies were first
(3k) quality assurance and, second, (3j) availability of me-
dicines; the third highest scored topic was (3a) geograph-
ical accessibility. When it comes to Sustainable Financing,
stakeholders wanted to increase knowledge mainly on
(4h) cost containment policies, (4e) health insurance co-
verage and models, and (4m) budget allocation to health.
This demonstrates the interest in research focused on
meso- and macro-level issues involved in Sustainable Fi-
nancing, rather than micro-, health service, or community
level topics in this domain.
Coherence analysis
How well do governments respond to the ATM needs of
populations?
Analysis of summary rankings indicates a high level of
coherence between current and desired policies in all
domains: coefficients of determination (R
2) vary from
0.46 for Health System Structure (with a high correlation
coefficient; r=0.68, P <0.01) to 0.86 for Sustainable Fi-
nancing (r= 0.93, P <0.01) – current policies, overall,
would cover adequate topics (Figure 1).
Despite the general coherence level observed, some
items (dots on scatter plots) are distant from trend lines
and should receive special consideration. Dots above trend
lines represent policies desired by stakeholders but not
sufficiently addressed by current policies – representing
policy gaps such as item (1e) staff capacity and training
for Rational Selection and Use of Medicines. The domain
with the lowest coherence indicator, Health System Struc-
ture, presented several gaps: (3p) promotion of research
and development – new drugs/neglected diseases; (3g) re-
sponsiveness to patients’ needs; (3n) governance: law en-
forcement; transparency and accountability; and (3f) staff
and technical capacity.
Is scientific evidence being generated to support policies
that respond to the needs of the population?
Research on Rational selection and use of medicines and
on Sustainable Financing seems to be addressing impor-
tant policy issues, which is indicated by high coherence
between current research and desired policies (r=0 .7 3,
P <0.05, R
2= 0.53; r= 0.80, P <0.01, R
2= 0.65, respectively).
Table 3 Respondent rankings of criteria that should be applied to define research priorities on access to medicines
*
Items (proposed criteria) Colombia Dominican
Republic
El Salvador Suriname E-mail
survey
Total
g Relevance (magnitude of the problem; persistence of the problem;
impact on health; urgency)
1.5 1.8 0.6 0.9 2.0 6.7
b Feasibility (capacity of the system to carry out the research; funding
support; justification of the cost/investment; justification of time)
0.8 1.0 0.8 0.7 0.7 4.1
i Research utilization (adequacy and usefulness of the current
knowledge base (avoiding duplication); applicability of the research
outcome; availability of cost-effective interventions (access);
operational effectiveness)
1.0 0.3 0.5 1.1 1.0 3.9
f Political will/acceptability/commitment 0.5 1.1 0.9 0.8 0.5 3.8
c Human rights issues; equity focus; ethical and moral issues 0.7 1.3 0.9 0.3 0.6 3.7
h Responsiveness to the National Health Policy or national goals 0.7 0.8 0.4 0.8 1.0 3.6
a Community concern/demand; environmental health and
sociopolitical effects
0.3 0.3 1.1 0.9 0.4 3.0
d Impact on development; economic impact 0.2 0.6 0.5 0.4 0.3 1.9
e Partnership building; research capacity building 0.3 0.2 0.0 0.1 0.4 1.0
*Item codes reflect the order in which they appeared in the questionnaire. Here they are presented according to total ranking scores. Bold numbers represent the
three highest scores in each setting.
Source: Authors.
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prescription and use of medicines (Rational Selection and
Use of Medicines), is highly prioritized as a desired policy
but does not figure amongst the main investigated topics.
Concerning Sustainable Financing,s o m ei t e m ss u c ha s
(4f) government budgets for medicines and (4h) cost con-
tainment policies represent highly desired policies, which
are not investigated as much (Figure 2).
The lowest coherence is observed for Health System
Structure (r= 0.49, P <0.05, R
2= 0.24). Equally important
policy issues as (3f) staff and technical capacity, (3k) qual-
ity assurance, and (3j) availability of medicines have diffe-
rent levels of research intensity, with a predominance of
the latter (3j). Also, highly prioritized policy issues like
(3a) geographical accessibility and (3b) distribution sys-
tems and supply chains received much less attention on
research. Items (3f), (3a), and (3b) could be considered
the most important research topics required to support
policies that respond to the needs of the population in this
domain.
Coherence between current research and desired pol-
icies is moderate for Pricing and Affordability (r=0.64,
P <0.05, R
2=0.41). In this dimension, (2g) policy and
regulation for medicines price and (2a) high out-of-
pocket payment are high priority issues that should be
addressed by public policies but they are not being in-
vestigated quite as much. On this domain, research on
(2i) patent and intellectual property issues is more inten-
sive, but it does not represent a highly ranked desired
policy.
Is research moving in the right direction?
High coherence between current research and desired re-
search indicates that topics currently being investigated at
Table 4 Summary ranking scores for current policies, desired policies, current research, and desired research
Item
codes
*
WHO Framework domain Current
policies
Desired
policies
Current
research
Desired
research Items (policy or research topics)
Rational Selection and Use of Medicines
1f Clinical treatment guidelines, and essential medicines list: development; incentives for
implementation; operational mechanisms; standardization (including between private
and public sectors)
17.7 12.4 9.8 9.8
1i Pharmacovigilance, information on adverse drug reaction, and other problems related
to medicines
10.1 8.0 6.9 7.6
1e Staff capacity for rational prescription and use of medicines; training curriculum 7.1 11.5 3.0 9.3
1d Impact of advertisements on medicines; incentives (or lack of, leading to private or
dual practice); medicines becoming a source in financing for health services
3.3 7.3 5.1 7.0
Pricing/Affordability
2g Policy and regulation for medicines price 11.4 10.9 5.7 9.4
2f Impact of prices on access 8.2 8.0 8.3 11.0
2a High out-of-pocket payment 7.6 9.1 5.3 8.8
2l Budget allocation to health 9.4 6.0 4.6 4.3
2i Patents and intellectual property issues 6.4 3.9 7.1 5.6
Reliable Health System/Health System Structure
3j Availability of medicines (especially in public sector) 8.8 6.3 8.3 7.2
3a Geographical accessibility: physical barriers; distance to facilities; remoteness
(combination of physical barriers and infrastructure weakness)
10.2 8.8 3.9 6.6
3k Quality assurance 6.8 6.8 4.0 8.6
3b Distribution systems and supply chains 8.5 7.9 3.9 5.3
3f Staff and technical capacity: for supply management; with managerial, interpersonal
and information technology (IT) skills, with local language skills (English)
5.1 6.8 1.8 5.3
3c Pharmaceutical services at local level 4.7 4.3 4.0 2.4
Sustainable Financing
4m Budget allocation to health 10.7 10.7 7.2 8.7
4e Health insurance coverage and models 9.4 10.7 7.4 8.9
4f Government budgets for medicines 10.8 11.0 5.4 7.8
4h Cost containment policies 6.9 9.1 5.1 10.4
*Item codes reflect the order in which they appear in the questionnaire. Top three summary scores in each domain marked in bold numbers.
Source: Authors.
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http://www.health-policy-systems.com/content/12/1/31national research centers seem to cover important re-
search topics, required for public health policies on
the domains of Rational selection and use of medi-
cines (r =0.71, P <0.05, R
2 =0 . 5 1) , Pricing and Afford-
ability (r =0.82, P <0.01, R
2 =0.67), and Sustainable
Financing (r =0.76, P <0.01, R
2 =0 . 58 ) (F igu re 3 ) . St aff
capacity and training for rational prescription and use
of medicines (1e), (2g) policy and regulation for medi-
cines price, (2a) high out-of-pocket payment, and (4h)
cost containment policies are highly desired research
topics that have not being investigated as much, represent-
ing important research gaps on these domains.
Health System Structure, the domain with the lowest
coherence indicator between current and desired research
(r=0. 61 ,P <0.01, R
2=0.38), presented several gaps: (3k)
quality assurance, (3a) geographical accessibility, and (3f)
staff and technical capacity. The latter (3f) presents the
same level of research desirability as other items (3l, 3d,
and 3b), but received less attention from research initia-
tives. Distance from trend line makes (3a) the most evi-
dent research gap on this domain.
Discussion
Ranson and Bennett [16] argue that HPSR priorities
should emerge from priority setting processes, but ad-
equate processes are rarely performed. They also refer to
a WHO survey performed in LMICs showing that often
policy-makers, researchers, and users of research are un-
aware of how priorities are identified or set. Further-
more, priority-setting exercises usually do not reflect a
Figure 1 Scatter plots between summary rankings for current and desired policies, by WHO Framework domain. Each dot represents a
policy/research item.
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does not consider views of stakeholders. This study de-
parted from the organization of issues pertaining to
ATM from a health systems perspective [12], and was
primarily based upon local level stakeholders’ inputs.
Even though policy/research items subject to rankings
were developed prior to stakeholders consultation, all
ranking lists included an open-ended “other” option with
the intention of encouraging respondents to add any issue
or topic deemed important and not adequately reflected
on the list. That option was rarely used by respondents,
which suggests that there was a good level of acceptance
and endorsement of the list supplied. Additionally, before
being asked to rank policy/research items, participants
were asked to expose their concerns on ATM policies and
research in an open-ended question, most of the topics or
issues that emerged from those answers were similar to
items listed in the ranking part of the questionnaire.
According to Viergever et al. [10], there are two main
groups of methods that can be applied to set priorities.
Consensus-based approaches involve putting people to-
gether and in line, allowing participants to reconsider
their positions, which tends to improve the acceptability
of outputs. However, a consensus-based approach would
be difficult for a regional exercise, and has been per-
formed for smaller scale exercises only. Metrics-based
Figure 2 Scatter plots between summary rankings for current research and desired policies, by WHO Framework domain. Each dot
representing a policy/research item.
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results by pooling individual rankings, which averts the
predominance of few most influential participants.
We derived data from individual responses, which were
aggregated statistically, aiming at means and averages and
looking for communalities rather than disagreements.
Therefore, there was no opportunity for participants to
confront their views and possibly change their positions to
generate consensus. The type of analysis performed is in-
novative in the field of priority-setting exercises. It es-
tablishes major research gaps and policy concerns both
directly through the analysis of summary scores, and
indirectly through linear regressions. The latter made
it possible to identify those policy/research items with
a gap between their degree of perceived implementation
(current policy/research rankings) and degree of desirabil-
ity (desired policy/research rankings). This could only be
done through the use of a metrics-based approach.
Tromp and Baltussen [17] suggest that an explicit con-
ceptual mapping of criteria facilitates decision making.
Even though they discuss priority setting of health inter-
ventions, and not health research as focused here, the
rationale of aggregating criteria in subsets was useful to
reduce the original list of criteria used in our study, and
helped define the final list of criteria submitted to re-
spondents. Although we have not used an explicit con-
ceptual mapping of criteria, there was an effort to form
groups of criteria with some shared meaning. Instead of
Figure 3 Scatter plots between summary rankings for current and desired research, by WHO Framework domain. Each dot representing
a policy/research item.
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ranking research items, we submitted the prioritization
exercise to a previous identification of relevant criteria
according to them. This was an attempt to capture re-
spondents’ normative standpoints towards research on
ATM. We tried to learn which criteria our pool of inter-
viewees and respondents consider legitimate and rele-
vant and were likely to have influenced their responses.
Also, it was a moment to reflect upon those criteria be-
fore ranking priorities – which could facilitate decision
when answering the questionnaire.
Stakeholder inclusiveness was an important concern of
this study, as suggested by Viergever [10]. Even though
we cannot assume that participants were statistically re-
presentative of all groups involved, we relied on good
choice of well-informed respondents and a balance among
the type of stakeholders to form an adequate pool of re-
spondents. PAHO local officers’ support was of utmost
importance in the identification of relevant national stake-
holders for the face-to-face interviews.
Viergever et al. [10] state that priority-setting exercises
should be based on agreed criteria. In our study, despite
some variation among countries, relevance, feasibility,
and research utilization were the most cited. They differ
from those agreed in an international consensus exercise
on ATM – innovation, impact on health and health sys-
tems, equity, and lack of research [13]. This may rely on
participants background and context of each exercise.
Stakeholders that contributed to our study were asked to
base their responses on their countries specificities, while
in the international exercise participants were asked to
consider the global scenario.
Setting priorities for health policy interventions is not
the same as setting priorities for research for health.
Groups of stakeholders affected by and interested in po-
licy decisions may differ from those usually interested or
involved in research on the same subject. Criteria that
are relevant to define policy intervention priorities also
differ from those that are adequate to judge how research
should be prioritized. This study addressed ATM-related
issues, expressed on the set of items submitted to ranking,
in which policy interventions can be designed and under
which research can be developed. As mentioned above,
this regional study contributed to a global initiative to
identify research topics under relevant policy issues [13].
Thus, important insight on how to proceed was gathered
mainly from literature on research for health priority
setting, but also from priority setting on health policy
interventions.
Clinical treatment guidelines and essential medicines
lists, pertaining to Rational Selection and Use of Medi-
cines, received the highest scores, indicating that this is
perceived as both an important current policy issue and
a highly desired one. It is perceived as a relevant ATM
research topic currently being investigated in the region,
and also a highly desired research topic. Since 1978,
WHO proposes rational selection as one of four key fac-
tors influencing ATM, and promotes the adoption of
essential medicines lists as a backbone for national phar-
maceutical policies [11,18,19]. This aspect was relevant in
a broader international research priority exercise [13] and
figures among the mostly addressed issues in peer re-
viewed publications in the region [14].
Staff capacity and training appeared as an important
gap, both for policy and for research, and among differ-
ent ATM domains. The policy gap on staff capacity for
rational selection and use of medicines is probably re-
lated to the growing need to adopt evidence-based prac-
tices [20], which demands skilled staff, generally scarce
in LMICs. Due to its importance, the health workforce
is stated as one of the health system building blocks
[21,22] remaining a worldwide priority and still an import-
ant gap [9,23]. A scoping study addressing peer reviewed
publication related to ATM in LAC also highlighted
human resources and health information as under-
represented themes in ATM research [14].
The need for policies addressing the development of
new medicines for neglected disease emerged as a gap,
showing the lack of treatment options for endemic dis-
eases is still prevalent in the region [24,25]. Tromp and
Baltussen [17] recognize responsiveness to the popula-
tion needs as one of the five categories that reflect the
goals of a health system. In our study it emerged as an
important policy gap. Another important policy gap,
good governance, has been increasingly recognized as
necessary for improving access to medicines and con-
tributing to health systems strengthening, since corrup-
tion and low transparency is an important cause of
wastage of scarce resources [26].
It is remarkable that the same issues appearing as
main gaps between current and desired policies – staff
capacity and training and cost containment policies –
also emerged as important research gaps. Geographical
accessibility and distribution systems and supply chains
appeared amongst highly desired policy issues that lack
research. Geographical accessibility figures as one of the
main research gaps. Many countries in Latin America
have their population concentrated in big cities, but have
large extensions of their territories with low population
density, generally low-income regions, not attractive to
private medicine suppliers.
This study presents some limitations. The response
rate was approximately 36% for the e-mail survey. Ne-
vertheless, this is consistent with the mean response rate
(34.6%, SD = 15.7%) reported on a meta-analysis devel-
oped by Cook et al. [27] for studies with no missing data.
The over-representativeness of academia and NGOs in
the e-mail survey was counterbalanced by interviews at
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was greater. A purposive sampling of countries was used
and results may not be generalized to other countries.
Different from other prioritization exercises on ATM
[13], we have decided – with regional stakeholders – not
to detail priorities as specific research questions. Our aim
was to map priority topics and to sensitize stakeholders
about the importance of evidence-based decision-making
and HPSR, motivating them to develop local research pri-
ority exercises. Thus, our results should not be taken as
top-down advice, but a support to decision makers on the
establishment of their own priorities, in which we agree
withTromp and Baltussen [17].
Conclusions
This study combines strong metrics approaches, such as
the coherence analysis, which contributes to priority set-
ting methodology development, with country and regional
level stakeholders’ participation. As part of a more com-
prehensive approach, which included a scoping study of
the scientific literature, it achieved useful results both at
country and regional levels, and also contributed to a glo-
bal exercise of research priority settings.
Staff and technical capacity, promotion of Research
and Development for new drugs for neglected diseases,
and responsiveness to patients’ needs, were the main
policy gaps. Human resources technical capacity, medi-
cines price regulation, out-of-pocket payments, cost con-
tainment policies, and quality assurance, were the main
research gaps identified.
In order to give feedback to the participants and in-
crease the chance of the results being used, an executive
summary of the final report was shared with the partici-
pants and PAHO officers. Also, results were presented
in an internet-based online lecture, with the same audi-
ence, apart from having been presented in other tech-
nical and scientific meetings. So far, we have not received
any feedback on the use of those priorities to support
decision-making on visited settings. We believe that the
influence of those exercises should merit itself some space
in future studies. We hope our study contributes to the
discussion and implementation of ATM research and pol-
icy priorities in LAC.
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